Aortic Root Thromboembolism and Associated Acute Myocardial Infarction in Patients With Contemporary Durable LVADs.

Autor:	Akdogan RE; Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina, USA., Check L; Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina, USA., Houston BA; Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina, USA., Carnicelli AP; Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina, USA., Griffin JM; Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina, USA., Atkins JL; Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina, USA., Witer LJ; Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, South Carolina, USA., Kilic A; Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, South Carolina, USA., Tedford RJ; Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina, USA., Baker G; Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina, USA., Manger D; Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina, USA., Hajj J; Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina, USA., Rao VN; Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina, USA.; The Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, South Carolina, USA.
Jazyk:	angličtina
Zdroj:	JACC. Case reports [JACC Case Rep] 2024 Aug 07; Vol. 29 (15), pp. 102441. Date of Electronic Publication: 2024 Aug 07 (Print Publication: 2024).
DOI:	10.1016/j.jaccas.2024.102441
Abstrakt:	Patients with HeartMate 3 left ventricular assist devices may develop aortic root thrombus, yet its prevalence and associated risks are unknown. We present 2 patients who developed aortic root thromboembolism and acute coronary occlusions. We additionally present heart transplantation as viable treatment for thromboembolic disease and refractory right ventricular failure. Competing Interests: Dr Houston has received grants from Medtronic and CVRx; and has received consulting fees from Edwards Lifesciences and Bioventrix outside of this work. Dr Kilic has received consulting and speaker fees from Abbott, Abiomed, 3ive, and LivaNova. Dr Tedford is the co-chair of the PH due to left heart disease task force for 7th World Symposium on Pulmonary Hypertension; is Deputy Editor for the Journal of Heart and Lung Transplantation; has received consulting fees from Abbott, Acorai, Aria CV Inc, Acceleron/Merck, Alleviant, Boston Scientific, Cytokinetics, Edwards LifeSciences, Gradient, Medtronic, Restore Medical, and United Therapeutics; has served on steering committee for Abbott, Edwards, Endotronix, and Merck; has served on the research advisory board for Abiomed; and he performs hemodynamic core lab work for Merck. Dr Hajj has received speaker fees from Abbott and Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to report.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu